13th week of 2009 patent applcation highlights part 35 |
Patent application number | Title | Published |
20090081108 | Clean bench and method of producing raw material for single crystal silicon - A clean bench comprising a worktable on which polycrystalline silicon is placed, a box part which includes side plates to surround three sides except a front face of a working space above the worktable, and a ceiling plate which covers an upper side of the working space. Supplying holes are formed in the ceiling plate of the box part, which supply clean air onto an upper surface of the worktable. An ionizer is provided, which ionizes the clean air supplied from the supplying holes to the working space and removes static electricity on the worktable. Suction holes are formed in the side plate of the box part, which suction air from the working space. | 2009-03-26 |
20090081109 | GaN CRYSTAL SHEET - A method forms a gallium nitride crystal sheet. According to the method a metal melt, including gallium, is brought to a vacuum of 0.01 Pa or lower and is heated to a growth temperature of between approximately 860° C. and approximately 870° C. A nitrogen plasma is applied to the surface of the melt at a sub-atmospheric working pressure, until a gallium nitride crystal sheet is formed on top. Preferably, the growth temperature is of 863° C., and the working pressure is within the range of 0.05 Pa and 2.5 Pa. Application of the plasma includes introducing nitrogen gas to the metal melt at the working pressure, igniting the gas into plasma, directing the plasma to the surface of the metal melt, until gallium nitride crystals crystallize thereon, and maintaining the working pressure and the directed plasma until a gallium nitride crystal sheet is formed. | 2009-03-26 |
20090081110 | GALLIUM NITRIDE-BASED MATERIAL AND METHOD OF MANUFACTURING THE SAME - Disclosed is a method of manufacturing a GaN-based material having high thermal conductivity. A gallium nitride-based material is grown by HVPE (Hydride Vapor Phase Epitaxial Growth) by supplying a carrier gas (G | 2009-03-26 |
20090081111 | Vanadia-Titania Aerogel Catalysts, Preparing Method of the Same, and Oxidative Destruction of Chlorinated Aromatic Compounds Using the Same - Disclosed are a vanadia-titania aerogel catalyst having high specific surface area and porosity, a method of preparing the same and a method of completely oxidatively-decomposing a chlorinated aromatic compound using the catalyst under air condition. The vanadia-titania aerogel catalyst of the invention is an aerogel form having many porosities and a high specific surface area obtained by performing a supercritical drying of vanadia-titania wet gel, which is prepared by a sol-gel method, with carbon dioxide and then firing the dried vanadia-titania, with a micro porosity structure being maintained, consists of vanadia and titania wherein a content of the vanadia is 1˜15 wt % of an overall catalyst weight. In addition, according to the invention, the vanadia-titania aerogel catalyst may further comprise a manganese oxide of 1-5 wt % or a sulfur component of 0.0001-1 wt %. Since the vanadia-titania aerogle catalyst of the invention has the very high conversion rate and selectivity for the complete oxidation reaction of the chlorinated aromatic compound and is very thermally stable, it can be usefully used in the oxidation reaction having a high heating value capable of generating local heat spots. | 2009-03-26 |
20090081112 | PROCESS AND APPARATUS FOR PRODUCING SUSPENSIONS OF SOLID MATTER - Method for producing nanosized calcium hydroxide crystals or particles, according to which method the calcium oxide-bearing initial material is brought into contact with carbon dioxide in the aqueous phase. Calcium carbonate crystals or particles are produced in a mixture, the pH of which is below 7. Using the present invention, it is possible to combine the two stages of producing CaCO | 2009-03-26 |
20090081113 | METHOD AND APPARATUS FOR GENERATING A CARBON NANOTUBE - In an apparatus and method of generating a carbon nanotube (CNT), a process chamber is heated to a target temperature and a catalyst powder is supplied into the heated process chamber. The catalyst powder moves in a first direction in the process chamber. A source gas is supplied into the process chamber in a second direction opposite to the first direction, so that the source gas delays the movement of the catalyst powder in the first direction and is reacted with the catalyst powder in the process chamber to thereby produce the CNT in the process chamber. Accordingly, the flow of the source gas against the flow of the catalyst powder reduces the drop velocity of the catalyst powder. Therefore, the source gas and the catalyst powder may be reacted with each other for a sufficiently long time. | 2009-03-26 |
20090081114 | Continuous Operation Type Active Charcoal Producing Apparatus and Process - A vertical multi-stage fluidized bed apparatus including a plurality of horizontal perforated partitioning plates disposed therein so as to partition the apparatus is provided, wherein an upper horizontal perforated partitioning plate is set to have a larger aperture rate than a lower horizontal perforated partitioning plate. From a lower part of the apparatus, feed carbon and fluidizing gas are continuously supplied so as to provide a gas superficial velocity in the fluidized bed which is 2-4 times a minimum fluidizing velocity of the feed carbon, thereby subjecting the feed carbon to fluidization with the fluidizing gas and activation with steam at 750-950° C. simultaneously to discharge activated carbon continuously from an upper part of the apparatus. As a result, activated carbon of even a high degree of activation is produced at a high yield comparable to that obtained in a batchwise operation. | 2009-03-26 |
20090081115 | METHOD AND APPARATUS FOR ACTUATING A CHEMICAL REACTION - Various disclosures of an oxygen generator apparatus and methods of using such are disclosed. | 2009-03-26 |
20090081116 | Rare vanadium derivative - The unique method of synthesis of chromium vanadate is performed using chromium chloride and sodium metavanadate. Methanol is used as a solvent. Zinc and/or palladium can be used as a catalyst. After reacting, the filtrate will be evaporated and the obtained substance is Chromium vanadate. The precipitate is sodium chloride. | 2009-03-26 |
20090081117 | Process For Preparing Aluminium Species - A static ion-exchange process for the preparation of a polynuclear Al species comprising the treatment of an aqueous aluminium chloride solution with a hydroxide-form ion-exchange resin at a temperature of from 5° C. to 60° C. for a period of at least 30 minutes. | 2009-03-26 |
20090081118 | Unknown - A storage medium for storing hydrogen as well as a process for storing hydrogen are described. | 2009-03-26 |
20090081119 | INHIBITING DNA POLYMERASE BETA TO ENHANCE EFFICACY OF ANTICANCER AGENTS - The invention provides anticancer methods. In one embodiment, the inventive method involves the co-administration to cancerous cells of (a) a chemotherapeutic agent, radiation, or a combination of a chemotherapeutic agent and radiation and (b) an inhibitor of DNA polymerase beta. In another embodiment, the invention provides anticancer methods involving the co-administration to cancerous cells of (a) a chemotherapeutic agent, radiation, or a combination of a chemotherapeutic agent and radiation and (b) an siRNA or shRNA in an amount sufficient to attenuate base excision repair within the cell. Another aspect of the invention relates to pharmaceutical compositions comprising an siRNA or shRNA that attenuates base excision repair. | 2009-03-26 |
20090081120 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods - The present application discloses methods and compositions for increasing patient tolerability during myocardial imaging comprising the administration of doses of caffeine and one or more adenosine A | 2009-03-26 |
20090081121 | LIPOSOME COMPOSITIONS USEFUL FOR TUMOR IMAGING AND TREATMENT - The invention relates to liposome compositions for delivering, for example, therapeutic, diagnostic, and imaging agents to a subject. Methods for preparing and using such liposome compositions are further provided. The compositions and methods of the invention find particular use in treating, diagnosing, and imaging a tumor in a subject. | 2009-03-26 |
20090081122 | Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant - The injectable formulation for treatment by hyperthermia comprises a liquid carrier and heat-generating superparamagnetic iron oxide nanoparticles having a mean diameter not greater than 20 nm. Said injectable formulation is able to form in-situ a hyperthermic solid or semi-solid implant upon contact with a body fluid or tissue. Said hyperthermic solid or semi-solid implant may be useful for treating a tumor or a degenerative disc disease by hyperthermia. | 2009-03-26 |
20090081123 | PHARMACEUTICAL COMPOUNDS - Tricyclic pyrazole derivatives of the following formula (I) having affinity for the cannabinoidergic CB1 and/or CB2 receptors: | 2009-03-26 |
20090081124 | VIRUS COAT PROTEIN/RECEPTOR CHIMERAS AND METHODS OF USE - The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occn-panty of co-receptor present on the cell, for example. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CCR5 and CXCR4 sequences. | 2009-03-26 |
20090081125 | Angiogenetic Agent Containing Adrenomedulin as the Active Ingredient - It is intended to provide an angiogenic agent which contains, as the active ingredient, at least one substance selected from the group consisting of adrenomedullin, a substance inhibiting the activity of adrenomedullin degrading enzyme, an adrenomedullin receptor activity-modifying protein, a calcitonin receptor-like receptor and an adrenomedullin receptor. | 2009-03-26 |
20090081126 | Novel fully human anti-VAP-1 monoclonal antibodies - Novel fully human anti-VAP-1 antibodies and fragments thereof are disclosed. Nucleic acids encoding anti-VAP-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-VAP-1 antibodies are also given. Pharmaceutical compositions comprising said antibodies and therapeutic uses thereof are also disclosed. | 2009-03-26 |
20090081127 | Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response - The present invention relates to a method of producing a plurality of dendritic cell/tumor cell hybrids which induce an anti-tumor response when applied to a patient. The present invention further relates to a method of producing a dendritic cell/tumor cell hybridoma which induces an anti-tumor response when applied to a patient. | 2009-03-26 |
20090081128 | Model of Alzheimer's Disease - A modified non-human warm-blooded vertebrate animal in which a biologically active human APP polypeptide is expressed, and in which function of its inducible Nitric Oxide Synthase (iNOS) protein is reduced as compared to a non-modified animal, methods of making the animal, and methods of testing a candidate composition for activity in the treatment of Alzheimer's Disease using the animal. | 2009-03-26 |
20090081129 | Bioluminescent Endoscopy Methods And Compounds - Bioluminescent endoscopy methods and compounds, wherein an anatomical object is examined by means of filling, perfusing, intubating, injecting, or otherwise administering a solution containing a bioluminescent substance or a mixture of luciferin and luciferase which produces bioluminescence, wherein a color or monochrome image of the object is constituted using the images and information based on bioluminescent emitted by the bioluminescent substance. Procedures are demonstrated which allow bioluminescent solutions to be perfused into certain tissue regions, such as but not limited to the common biliary duct, genitourinary tract, gastro-intestinal tract, cardiovascular system and lymphatic system wherein said structures may be conveniently visualized during surgery to avoid damage to these structures. Such images may also be combined with visual light images. Methods of detection of cancer cells using bioluminescence are provided. Preferred embodiments disclosed include membrane permeant coelenterazine analogs. | 2009-03-26 |
20090081130 | MICROPARTICLES USEFUL AS ULTRASONIC CONTRAST AGENTS AND FOR DELIVERY OF DRUGS INTO THE BLOODSTREAM - Microparticles are provided comprising a shell of an outer layer of a biologically compatible material and an inner layer of biodegradable polymer. The core of the microparticles contain a gas, liquid or solid for use in drug delivery or as a contrast agent for ultrasonic contrast imaging. The microparticles are capable of passing through the capillary systems of a subject. | 2009-03-26 |
20090081131 | TUMOR THERAPY WITH HIGH AFFINITY LAMININ RECEPTOR-TARGETED VECTORS AND COMPOUNDS - The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis. | 2009-03-26 |
20090081132 | Water-borne aerosol composition - A water-borne aerosol composition containing an oil soluble insecticidal component (A), a hydrophobic organic solvent (B), water (C), a non-ionic surfactant (D) and a propellant (E), wherein the oil soluble component (A) is 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate and wherein the non-ionic surfactant (D) has a HLB in the range of 4.1 to 7.0, shows an excellent insecticidal activity and is useful. | 2009-03-26 |
20090081133 | Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations - Mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients. | 2009-03-26 |
20090081134 | Oral Care Compositions Comprising Tropolone Compounds and Essential Oils and Methods of Using The Same - The present invention relates to oral care compositions suitable for preventing or treating diseases or conditions of the oral cavity in warm-blooded animals including humans, comprising an oral care effective amount of at least one tropolone compound in combination with at least one essential oil, and a pharmaceutically acceptable oral carrier. This invention further relates to a method for preventing or treating diseases or conditions of the oral cavity in warm-blooded animals including humans, by applying an oral care effective amount of the oral care composition to the oral cavity. | 2009-03-26 |
20090081135 | Iodine-based oral antibacterial treatment methodology - An iodine-based oral antibacterial treatment methodology involves applying an effective amount of an iodine-based oral antibacterial treatment to the inside of a human or animal mouth in the gum area between the gum and a tooth wall. The delivered treatment includes available iodine, including molecular iodine, and an iodine free radical initiator selected from the group consisting of chloride ions, bromide ions and mixtures thereof. Animals include pets, such as dogs and cats, as well as farm animals having teeth, e.g., horses, cows, goats and the like, and zoo animals having teeth, such as chimps, baboons, tigers and the like. | 2009-03-26 |
20090081136 | Compositions Useful For Tooth Whitening - The present invention provides tooth whitening compositions in the form of a liquid crystal or a microemulsion that includes a tooth whitening agent in an amount effective to whiten teeth, a hydrophilic phase including water, a hydrophobic phase including at least one oil, at least one anionic, nonionic, amphoteric or zwitterionic surfactant, and a water soluble co-solvent having a Hildebrand solubility parameter above 12 (cal/cm | 2009-03-26 |
20090081137 | Crosslinked Polytetrahydrofuran-Containing Polyurethanes - The invention relates to a cross-linked polyurethane, which contains, in an integrated manner, at least one polytetrahydrofuran and one polyisocyanate mixture, to cosmetic or pharmaceutical agents containing a polyurethane of the aforementioned type, and to the use of these polyurethanes. | 2009-03-26 |
20090081138 | CANCER CHEMOPROTECTIVE COMPOSITIONS AND NATURAL OILS AND METHODS FOR MAKING SAME - Cancer chemoprotective compositions containing reduced oil-content extraction meals made from plants containing natural oils and glucosinolates. The oil content of the extraction meals may be reduced using batchwise or continuous supercritical fluid extractions. Also provided are glucosinolate-rich compositions containing purified glucosinolates isolated from plant materials. The glucosinolate-rich compositions may be made by reducing the oil content of a plant materials containing natural oils and glucosinolates and isolating the glucosinolates from the reduced oil-content plant materials using a membrane extraction. Natural oils containing isothiocyanates are also provided. The natural oils are well-suited for use in skin and hair care products. | 2009-03-26 |
20090081139 | Water-based delivery systems - The invention relates to a water-based delivery system for an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising water, a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor. | 2009-03-26 |
20090081140 | 6-METHYL-4-(2',2',3'-TRIMETHYL-3'-CYCLOPENTEN-1'-YL)-2-CYCLOHEXEN-1-OL AS SANDAL ODORIFEROUS SUBSTANCE - The invention relates to a compound of the formula (VII) | 2009-03-26 |
20090081141 | TOPICAL USE OF THIAZOLIDINE DERIVATIVES AGAINST CONSEQUENCES OF OXIDATIVE STRESS OF SKIN - A cosmetic composition intended for protecting skin against stress generating free radicals or reactive oxygen species is disclosed. The cosmetic composition comprises a physiologically compatible excipient and a thiazolidine compound. Methods of protecting skin generally and against cutaneous consequences of oxidative stress are also disclosed. | 2009-03-26 |
20090081142 | External Preparation for Skin - An external preparation for the skin containing isononyl 2-ethylhexanoate and/or 2-ethylhexyl 2-ethylhexanoate (i.e., component (a)); an oil-in-water emulsion type skin cosmetic composition containing the ingredient (a), (b) one or more ingredients selected from higher fatty acids and higher alcohols which are solid to semi-solid at an ordinary temperature (25° C.), (c) a homopolymer, copolymer, cross polymer, or mixture containing one or more ingredients selected from 2-acrylamide-2-methylpropane sulfonic acid and acrylic acid and its derivatives as constituent units and (d) one or more ingredients selected from nonionic surfactants having an HLB value of 9 or more; and an oil-in-water or a water-in-oil emulsion type sunscreen cosmetic composition containing (a) 2-ethylhexyl 2-ethylhexanoate and/or isononyl 2-ethylhexanoate, (b) an ultraviolet absorber, (c) an ultraviolet scatterer and (d) a silicone oil. | 2009-03-26 |
20090081143 | Extracts From Black Yeast For Whitening Skin - The present invention relates to topical skin whitening compositions comprising a whitening effective amount of a black yeast-derived melanin-degrading enzyme extract and a method of preparing the compositions. The compositions provide a whitening effect by degrading melanin on the surface of the skin, the hair and the nails. The enzyme extract can be derived from | 2009-03-26 |
20090081144 | COSMETIC COMPOSITIONS - A topical composition having (i) an isolated polypeptide having the sequence of SEQ ID NO: 1 or a functional equivalent thereof, and (ii) a cosmetically acceptable carrier; and use thereof. | 2009-03-26 |
20090081145 | PROCESS FOR FORMING DISULPHIDE BRIDGES - The present invention relates to an improved method of formation of disulfide bridges in substances bearing SH groups, in particular peptides, for example by formation of intramolecular disulfide bridges, in which a heterocyclic compound having at least one nitrogen atom (e.g. caffeine or a caffeine-like substance) is used for catalysis of the reaction. It was found, surprisingly, that addition of the heterocyclic substance increases both the yield and the purity of the product bearing disulfide bridges. | 2009-03-26 |
20090081146 | HAIR DYEING COMPOSITION - Provided is a hair dyeing composition, containing a first part containing (a) a nitrogen-containing compound expressed by the general formula (1) or a salt thereof and a second part containing a component (b) of an oxidizing agent, wherein a pH upon use is 7.5 to 12, | 2009-03-26 |
20090081147 | PERMANENT WAVING AGENT - A permanent waving agent is capable of permanent waving and coloring hair simultaneously. | 2009-03-26 |
20090081148 | PROTECTION OF KERATINOUS FIBERS USING CERAMIDES AND/OR GLYCOCERAMIDES - The present invention relates to a composition for the protection of keratinous fibers containing at least one compound chosen from ceramides and glycoceramides, at least one cationic polymer, and at least one amphoteric polymer; to a process and kit for protecting keratinous fibers from damage caused by chemical treatment by applying, prior to chemical treatment, to the keratinous fibers a leave-in composition comprising at least one compound chosen from ceramides and glycoceramides. | 2009-03-26 |
20090081149 | Skin And Hair Care - A fermentation product of soya bean extract, e.g. soya milk, provides conditioning benefits for skin, particularly moisturising benefits, namely increased moisture, and conditioning benefits for hair, particularly reduction of fly away behaviour and improved curl retention. | 2009-03-26 |
20090081150 | CYCLOPROPANATED MACROCYCLIC KETONES AND LACTONES - The present invention is directed to novel cyclopropanated macrocyclic ketone and lactone compounds of the general formula: | 2009-03-26 |
20090081151 | Olefin wax, silicone-modified olefin wax, silicone-modified room temperature-solidifying composition using the wax, and cosmetics using them - An olefin wax (A) is (i) a copolymer (A1) obtained by copolymerizing ethylene and at least one diene or a copolymer (A2) obtained by copolymerizing ethylene, at least one olefin selected from α-olefins of 3 to 12 carbon atoms and at least one diene; wherein (ii) the content of unsaturated groups per one molecule is in the range of 0.5 to 3.0 groups; (iii) the density is in the range of 870 to 980 kg/m | 2009-03-26 |
20090081152 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF MAKING SAME - This invention relates to a process of making a group of silylated poly(N-alkyl-4-vinylpyridinium) quaternized salts suitable for use as coating materials for the treatment of substrate surfaces to impart an antimicrobial effect. | 2009-03-26 |
20090081153 | COMBINATION OF SYNTHETIC ANTIMICROBIAL POLYMERS AND SESQUITERPENOID COMPOUNDS - The present invention provides compositions comprising a synthetic antimicrobial polymer and/or oligomer and a sesquiterpenoid compound useful in reducing the growth of microbes. | 2009-03-26 |
20090081154 | Attractant composition for yellowjackets - Disclosed is a new attractant composition for yellowjacket wasps, which contains certain esters of butyric acid known to be attractive to yellowjackets, such as heptyl butyrate, octyl butyrate, or other esters of butyric acid, in combination with certain plant volatiles (kairomones), including trans-2-hexenol and methyl salicylate, said kairomones being used in combination with said esters of butyric acid to achieve an enhanced or synergistic attractiveness to yellowjackets. The new attractant composition is significantly more attractive to yellowjackets than the known attractant esters heptyl butyrate and octyl butyrate when used either singly or together. | 2009-03-26 |
20090081155 | Use of Inhibitors of Indoleamine-2,3-Dioxygenase in Combination with Other Therapeutic Modalities - The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent. | 2009-03-26 |
20090081156 | Bioactive molecular matrix and methods of use in the treatment of disease - The present invention provides methods and compositions for stimulating an immune response or modulating cell signal transduction in a host by administering to said host a composition comprising at least three biomodulatory molecules connected by at least one cross-linking agent forming a chain or matrix wherein the chain or matrix functions as an immuno-stimulatory adjuvant to activate an immune accessory cell. | 2009-03-26 |
20090081157 | Immunostimulatory Combinations for Vaccine Adjuvants - This invention discloses immunostimulatory combinations of Tumor Necrosis Factor Receptor Superfamily (TN-FRSF) agonists, Toll-Like Receptor (TLR) agonists, “domain present in NAIP, CIITA, HET-E, TP-I (NACHT)-Leucine Rich Repeat (LRR)” or “NLR” agonists, RIG-I-Like Helicase or “RLH” agonists, purinergic receptor agonists and cytokine/chemokine receptor agonists, together with delivery methods. The combinations, when used alone at the site of pathology, provide immunostimulation that induces host humoral and cellular immunologic responses to eliminate pathogens or neoplasms. Alternatively, when the combinations are used with a defined antigens, these combinations can induce focused humoral and cellular immunologic responses useful as prophylactic and/or ameliorative therapeutic modalities for infections and the treatment of neoplastic disorders. | 2009-03-26 |
20090081158 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV - Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formulas IV, IV′, I″, II″, or IVa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. | 2009-03-26 |
20090081159 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING OPHTHALMIC DISORDERS - The present invention relates to compositions and methods for the detecting, treating, and conducting research on ophthalmic disorders associated with photoreceptor cell death and/or retinal insult. In particular, the present invention provides compositions and methods for increasing IL-6 expression and/or activity (e.g., exogenous IL-6), activating IL-6 receptors (e.g., IL-6R, sIL6-R), activating pathway related compounds (e.g., STAT, FLIP), and/or activating related pathways (e.g., JAK/STAT pathway, TGF-β pathway, Ahr pathway) in the diagnosis, treatment, and conducting research of ophthalmic disorders associated with photoreceptor cell death and/or retinal insult (e.g., retinal detachment). | 2009-03-26 |
20090081160 | Method for reducing the likelihood of implantation failure during an assisted reproduction in a subject - Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of an embryo. | 2009-03-26 |
20090081161 | Treatment of neoplasms with viruses - The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy. | 2009-03-26 |
20090081162 | METHOD FOR DOWNREGULATING AN IMMUNE REACTION - Ongoing pathogenic immune reactions and the severity of an incipient or prospective immune reaction may be downregulated or reduced by locally administering Type I interferon at a site remote from the ongoing, incipient or prospective immune reaction. The amount of interferon to be administered is that which is effective to induce trafficking of antigen-presenting cells to the site of interferon administration, and away from the site of the immune reaction. It is administered in the course of the ongoing immune reaction, or concurrently with the provocation of an immune reaction. | 2009-03-26 |
20090081163 | CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS - The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be orally administered and wherein re-treatments are possible. | 2009-03-26 |
20090081164 | Use of a cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said cyclosporin - This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity. | 2009-03-26 |
20090081165 | BICYCLIC HETEROARYL DERIVATIVES - Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections. | 2009-03-26 |
20090081166 | Colonization factor (CF) antigens of enterotoxigenic escherichia coli in recombinant bacteria - strains, such as enterotoxigenic | 2009-03-26 |
20090081167 | FOLIC ACID PRODUCING BIFIDOBATERIUM BACTERIAL STRAINS, FORMULATIONS AND USE THEREOF - The present invention relates to folic acid-producing bacterial strains belonging to the genus | 2009-03-26 |
20090081168 | METHOD OF FORMING A PEPTIDE-RECEPTOR COMPLEX WITH ZSIG33 - The present invention relates to a method of forming a peptide-receptor complex with zsig33 polypeptides and their receptors as well as antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included. | 2009-03-26 |
20090081169 | METHOD FOR OSTEOGENIC DIFFERENTIATION OF BONE MARROW STEM CELLS (BMSC) AND USES THEREOF - Methods for obtaining osteoprogenitors, osteoblasts or osteoblast phenotype cells, as well as cell populations including such cells, from human bone marrow stem cells in vitro or ex vivo are disclosed. Bone marrow stem cells are contacted with human serum or plasma and a growth factor or a biologically active variant or derivative thereof. In addition, osteoprogenitor, osteoblast or osteoblast phenotype cell types and cell populations are provided. The cell populations may include additional cell types, such as endothelial cells or progenitors. The osteoprogenitors, osteoblasts or osteoblast phenotype cells may be used in therapy, particularly bone therapy. | 2009-03-26 |
20090081170 | Cardiac progenitor cells - The present invention relates to the field of progenitor cells, and in particular to the field of cardiac progenitor cells. More particularly, the present invention pertains to the identification of a population of progenitor cells in the adult mammalian heart that is capable of giving rise to significant levels of de novo cardiomyocytes with the potential to replenish injured muscle post-infarction and/or promote neovascularisation to bring about complete cardiac regeneration. Accordingly, the present invention relates to methods for generating a population of mammalian post-natal epicardium derived cells (EPDCs), populations of EPDCs so generated, and methods of using same. | 2009-03-26 |
20090081171 | Cell system for alleviating syndromes of Parkinson's disease in a mammal - A cell system for treating neurodegenerative disorders in a mammal is provided. The cell system includes a population of neurons differentiated from umbilical mesenchymal stem cells for expressing at least one of tyrosine hydroxylase (TH), dopamine-β-hydroxylase (DBH), glutamate decarboxylase (GAD), aromatic L-amino acid decarboxylase (AADC) and dopaminergic transporter (DAT) in a cell culture. A method for treating neurodegenerative disorders in a mammal is also provided. The method comprises the steps of differentiating umbilical mesenchymal stem cells into a population of neurons that express at least one of TH, DBH, GAD, AADC and DAT in a cell culture, and transplanting the population of neurons into the brain of the mammal. | 2009-03-26 |
20090081172 | THERAPEUTIC AND DIAGNOSTIC CLONED MHC-UNRESTRICTED RECEPTOR SPECIFIC FOR THE MUC1 TUMOR ASSOCIATED ANTIGEN - The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC). The invention provides a method of activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a T cell receptor | 2009-03-26 |
20090081173 | METHODS AND COMPOSITIONS INVOLVING BACTERIOPHAGE ISOLATES - Disclosed are methods of increasing the virulence of a bacteriophage, comprising contacting a bacteriophage with a composition comprising a bacterium or bacterial extract; and a polymer. Also disclosed are methods of propagating and isolating therapeutic bacteriophages that involve use of dilute polymer compositions. Also disclosed are pharmaceutical compositions the bacteriophage for which virulence has been increased by the methods set forth herein or which have been isolated by the methods set forth herein. | 2009-03-26 |
20090081174 | Synergistic fungicidal compositions - Fungicidal compositions are described, consisting of mixtures comprising a copper (II) salt of phosphorous acid and at least another metallic salt of phosphorous acid or consisting of mixtures comprising a copper (II) salt of phosphorous acid, alone or mixed with at least another metallic salt of phosphorous acid, and one or more fungicidal compounds, and their use for the control of phyto-pathogen fungi. | 2009-03-26 |
20090081175 | Method for Treating Disseminated Cancer - The present invention discloses an immunotherapeutic method for treating a patient suffering from a disseminated cancer by administering expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtainable from one or more metastasis-draining lymph nodes (metinel nodes) draining a metastasis. The method comprises identification of one or more metinel lymph nodes in a patient, resection of the one or more nodes and, optionally all or part of the metastases, isolation of metastasis-reactive T-lymphocytes from said lymph nodes, in vitro expansion of said metastasis-reactive T-lymphocytes, and administration of the thus obtained T-lymphocytes to the patient, wherein the T-lymphocytes are CD4+ helper and/or CD8+ T-lymphocytes. | 2009-03-26 |
20090081176 | Cure for the human immunodeficiency virus - A method whereby a cure is found for the Human Immunodeficiency Virus (HIV) by rebuilding and stimulating the infected individual's immune system. | 2009-03-26 |
20090081177 | Methods and compositions for improving pregnancy outcome - A method of increasing pregnancy rate in a female subject is provided, the female subject or an oocyte for introduction into the female subject being fertilized by a sperm from a male subject. The method includes the steps of administering to the male subject prior to fertilization: (i) an effective amount of an anti-oxidant agent; and (ii) an effective amount of an agent that reduces inflammation in the male reproductive tract and/or an effective amount of an agent that increases testicular testosterone concentration. | 2009-03-26 |
20090081178 | Phenolic Binding Peptides - The present application relates to peptides which bind to tannin, polyphenolic or anthocyanin compounds, and particularly to tea and wine stains on a fabric or other surface. The invention also concerns binding peptide conjugates which includes a binding peptide coupled to an agent and the use of the binding peptide conjugate for delivering an agent to a desired target. | 2009-03-26 |
20090081179 | METHOD FOR REDUCING THE SEVERITY OF NEUROLOGICAL DISORDERS - The present invention relates to the use of
| 2009-03-26 |
20090081180 | ANTIMICROBIAL POLYMER CONJUGATES - Water-soluble polymer conjugates of antimicrobial agents retaining at least a portion of the antimicrobial activity of the agent, pharmaceutical compositions containing the polymer conjugates, and methods for treating microbial infections with the pharmaceutical compositions. | 2009-03-26 |
20090081181 | ISOLATION OF GROWTH AND DIFFERENTIATING FACTORS FROM COLOSTRUM - The present invention concerns a novel process for isolating growth and differentiating factors present in colostrum, all in a natural way. This process is characterized by maturation steps (controlled mild acid hydrolysis) and physical steps (molecular filtration) which optimize recovery of measured growth factors and their ability to entice a response on human cells. Advantageously, this process allows the derivation and isolation of growth and differentiating factors with highly disparate sizes (or molecule weights) in pools. These pools can be used in select and varied ways, including cosmetic, cosmeceutical, nutraceutical, dermatological, pharmaceutical, medical and veterinary applications. It can also be used as a replacement to fetal calf serum to promote cell proliferation, and above all, cell differentiation. | 2009-03-26 |
20090081182 | Modified Lecithin-Cholesterol Acyltransferase Enzymes - The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, coronary heart disease, thrombosis, and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide. | 2009-03-26 |
20090081183 | HIV Transcription Repressor Complex and Compositions and Methods Based Thereon - The molecular mechanism of YY1/LSF-associated repression of HIV-1 is described herein. More particularly, an HIV transcription repressor complex containing YY1, LSF and HDAC1 is described. The invention is based on our discovery that (1) HDAC1 co-purifies with the LTR-binding YY1-LSF repressor complex; (2) the domain of YY1 that interacts with HDAC1 is required to repress the HIV-1 promoter; (3) the expression of HDAC1 augments repression of the LTR by YY1, and (4) the deacetylase inhibitor trichostatin-A blocks repression mediated by YY1. This novel link between HDAC1 recruitment and inhibition of HIV-1 expression by YY1 and LSF, in the natural context of a viral promoter integrated into chromosomal DNA, supports novel HIV therapies described herein and has significant implications for the long-term treatment of AIDS. | 2009-03-26 |
20090081184 | NON-PANCREATIC PROTEASES FOR CONTROLLING PLASMA CHOLECYSTOKININ (CCK) CONCENTRATION AND FOR TREATING PAIN - This invention relates to methods for maintaining the basal level or reducing the level of cholecystokinin (CCK) in blood plasma of a mammal. Additionally, the invention provides methods for treating pain in a mammal and more particularly, methods for treating abdominal pain in a mammal. The methods include administering to the mammal a non-pancreatic protease or a composition comprising a non-pancreatic protease. The methods of this invention are particularly useful for treating abdominal pain in a mammal suffering from acute or chronic pancreatitis and related conditions. | 2009-03-26 |
20090081185 | Apoptotic agents - A complex at least formed from at least one component A and at least one component B, wherein component A has a binding activity for cellular surface structures, and component B carries a protease or derivatives thereof as an effector function. | 2009-03-26 |
20090081186 | METHODS AND COMPOSITIONS FOR PREVENTING AND/OR TREATING PANCREATITIS - The present invention relates to a method of preventing and/or treating pancreatitis in a subject, the method including administering to the subject a therapeutically effective amount of a Galanin antagonist and/or a Galanin receptor antagonist. | 2009-03-26 |
20090081187 | Pharmacological vitreolysis - A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy. | 2009-03-26 |
20090081188 | GLYCOPEGYLATED FACTOR IX - The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 2009-03-26 |
20090081189 | Process for in vitro differentiation of neuronal stem cells or of cells derived from neuronal stem cells - The process for in vitro differentiation of neuronal stem cells comprises contacting the cells with a substance which inhibits a reaction of the Wnt signal transduction pathway, and culturing of said cells under conditions which enable said cells to propagate and/or differentiate. | 2009-03-26 |
20090081190 | Methods for Antibody Library Screening - The present invention provides an improved method of screening a library of molecules to identify or select one or more members thereof which are candidate binding partners for one or more target entities: (a) contacting an expression library with one or more target entities; (b) subjecting said target entities to at least one washing step; (c) separating target entities which have become bound to one or more members of the expression library from unbound members of the expression library by separation through an organic phase, thereby separating candidate binding partners for said target entities from other library members. | 2009-03-26 |
20090081191 | Antibodies that bind human 17-A1/EpCAM tumor antigen - The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP or GA 733-2. Also provided are pharmaceutical compositions comprising the aforementioned antibodies or fragments thereto. | 2009-03-26 |
20090081192 | METHODS OF SCREENING FOR COMPOUNDS HAVING ANTI-INFLAMMATORY ACTIVITY - A method screens compounds out of the group consisting of proteins, peptides, peptidomimetics, antibodies and small organic molecules that increase the activity of the protein Rac1 by virtue of their binding to the extracellular portion of this protein. The method includes the steps of: contacting a confluent layer of cultured endothelial cells with at least one of test compounds, lysing the endothelial cells with a lysation buffer, and measuring the amount of Rac1 activity. | 2009-03-26 |
20090081193 | HEMAGGLUTININ POLYPEPTIDES, AND REAGENTS AND METHODS RELATING THERETO - The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto. | 2009-03-26 |
20090081194 | COMPOSITIONS AND METHODS FOR REDUCING RISK OF DEVELOPMENT, OR SEVERITY, OF INAPPROPRIATE IMMUNE RESPONSE IN EYES - A composition for reducing the risk of development, or severity, of an inappropriate immune response in an eye comprises an antagonist to at least a human TLR, an antagonist to at least a coreceptor of human TLR, a compound that is capable of inhibiting an activation of a human TLR signaling pathway, or a combination thereof. The composition can be used to reduce the risk of development, or severity, of contact lens-associated corneal infiltrates. The composition can be formulated into an eye drop or a contact lens-treating, -storing, -cleaning, -disinfecting, or -wetting solution. | 2009-03-26 |
20090081195 | Inhibitors of Ste20-like Kinase (SLK) and Methods of Modulating Cell Cycle Progression and Cell Motility - The invention provides inhibitors of Ste20-like kinase (SLK inhibitors). The inhibitors may be employed to modulate proliferation of cells, including tumor and cancer cells. The inhibitors also may be employed to inhibit motility or migration of cells, including cancer and tumor cells. | 2009-03-26 |
20090081196 | Medicaments for fungal infections - The protein CAMP65p of | 2009-03-26 |
20090081197 | Methods for Selection of Melanocortin Receptor-Specific Agents for Treatment of Obesity - Provided are methods for selecting melanocortin receptor-specific compounds for attenuating food intake and for treatment of specific disease conditions, including treatment of obesity and related energy homeostasis or feeding disorders characterized by excess weight gain, without inducing a sexual response, and methods for selecting compounds for treatment of sexual dysfunction. Further provided are pharmaceutical preparations defined by such methods, and methods and preparations for attenuating food intake and treatment of said conditions. | 2009-03-26 |
20090081198 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE - The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen. | 2009-03-26 |
20090081199 | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof - Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders. | 2009-03-26 |
20090081200 | Tissue Factor Antibodies and Uses Thereof - The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the invention. | 2009-03-26 |
20090081201 | Methods for Identifying Compounds For the Treatment of Type 1 Diabetes - The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic β cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic β cells. | 2009-03-26 |
20090081202 | IMMUNOGENIC COMPOSITIONS AND METHODS - Disclosed are immunogenic compositions, and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating microbial infection, including, for example, influenza, or one or more symptoms thereof. | 2009-03-26 |
20090081203 | Methods for treating lymphomas in certain patient populations and screening patients for said therapy - Methods for predicting a response of a patient having a lymphoma to a therapy regimen of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione using prognostic factors of a patient's disease burden, absolute lymphocyte count or time since last rituximab therapy are disclosed. Specific methods of treating a lymphoma encompass the administration of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione to a patient who has one or more of the favorable profiles, alone or in combination with immunosuppressive agents such as rituximab. | 2009-03-26 |
20090081204 | SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGOUS TO AMYLOID BETA FOR INDUCTION OF AN IMMUNE RESPONSE TO AMYLOID BETA AND AMYLOID DEPOSITS - The present invention relates to synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid β which can be used alone or conjugated to an immunostimulatory molecule in an immunizing composition for inducing an immune response to amyloid β peptides and amyloid deposits. | 2009-03-26 |
20090081205 | CONTINUOUS DOSING REGIMENS FOR NEURAL STEM CELL PROLIFERATING AGENTS AND NEURAL STEM CELL DIFFERENTIATING AGENTS - The present invention provides effective dosing regimes for neural stem cell proliferating agents, kits containing effective dosing regimes for neural stem cell proliferating agents, and uses thereof. In particular, neural stem cell proliferating agents, such as hCG, prolactin and EPO are delivered to mammalian subjects at low doses in a continuous fashion over several days, as opposed to delivery of high doses in a short period of time. | 2009-03-26 |
20090081206 | METHOD AND PHARMACEUTICAL COMPOSITION FOR INHIBITING PREMATURE RAPTURE OF FETAL MEMBRANES, RIPENING OF UTERINE CERVIX AND PRETERM LABOR IN MAMMALS - A method and a pharmaceutical composition for inhibiting premature rapture of the fetal membranes, ripening of the uterine cervix and preterm labor of female mammals including human. The method includes the step of administering compounds for reversing at least two biochemical conditions being associated with the above processes. The pharmaceutical composition includes compounds for reversing at least two biochemical conditions being associated with the above processes. | 2009-03-26 |
20090081207 | High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity - The present invention relates to recombinant human or humanized polypeptides which bind to α5β1 integrin with high affinity and blocking function. Further, diagnostic and pharmaceutic applications of the potypeptides are disclosed. | 2009-03-26 |